JK07
Phase 2Small molecule
JK07 is one of 56 small molecule programs targeting Pulmonary Hypertension. It is currently in Phase 2.
2
Indications
4
Total Trials
2
Active Trials
55
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
687 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerPreclinical
Brethine
SanofiPreclinical
Medrol
PfizerPreclinical
LCZ696
NovartisPreclinical
Zemplar
AbbViePreclinical
Activase
RochePreclinical
Savaysa
Daiichi SankyoPreclinical
JK07
SSalubris Biotherapeutics Inc
Phase 2
Xifaxan
SSalix
Preclinical
Coumadin
AAbbott
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Heart Failure2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JK07. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSalubris Biotherapeutics Inc